<DOC>
	<DOCNO>NCT01746420</DOCNO>
	<brief_summary>The purpose study determine whether recombinant human platelet-derived growth factor ( rhPDGF-BB ) Injection effective treatment lateral epicondylitis ( tennis elbow ) .</brief_summary>
	<brief_title>Phase II Study Effects rhPDGF-BB Injection Lateral Epicondylitis</brief_title>
	<detailed_description />
	<mesh_term>Tennis Elbow</mesh_term>
	<mesh_term>Platelet-derived growth factor BB</mesh_term>
	<criteria>1 . Subject sign Institutional Review Board ( IRB ) approve Informed Consent Form specific study prior enrollment 2 . Subject clinical diagnosis lateral epicondylitis 3 . Subject 's symptom reproduce resisted supination wrist dorsiflexion 4 . Subject 's symptom persist least 3 month despite conservative treatment include one combination : 1 . Physical therapy 2 . Splinting 3 . Nonsteroidal antiinflammatory drug ( NSAID ) 4 . Corticosteroid injection 5 . Subject independent , ambulatory , comply postinjection evaluation visit 6 . Subject 2180 year age consider skeletally mature 1 . Subject undergone previous corticosteroid injection therapy effect elbow less three month prior enrollment 2 . Subject receive previous Platelet Rich Plasma ( PRP ) injection affect elbow 3 . Subject deem require corticosteroid injection affect elbow course study 4 . Subject use chronic medication know affect skeleton ( e.g . glucocorticoid usage &gt; 10mg/day ) 5 . Subject undergone surgical intervention affect elbow treatment lateral epicondylitis 6 . Subject positive medical history following : 1. medial epicondylitis 2. radial tunnel syndrome 3. carpal tunnel syndrome 4. septic gouty arthritis 5. cervical radiculopathy 6. trauma affect elbow within past 6 week 7. neuromuscular musculoskeletal deficiency , limit ability perform functional measurement ( e.g . grip strength test ) 7 . Subject currently acute infection injection site 8 . Subject test positive treated malignancy past suspected malignancy currently undergo radio chemotherapy treatment malignancy anywhere body , whether adjacent distant propose rhPDGFBB Injection treatment site 9 . Subject physically mentally compromise ( e.g . currently treat psychiatric disorder , senile dementia , Alzheimer 's disease , etc . ) extent Investigator judge subject unable unlikely remain compliant 10 . Subject allergy yeastderived product 11 . Subject receive investigational therapy approve therapy investigational use within 30 day injection procedure followup phase study 12 . Subject prisoner , know suspect transient 13 . Subject 's condition represent worker 's compensation case 14 . Subject currently involve healthrelated litigation procedure 15 . Subject documented evidence history ( e.g . liver test ) drug/alcohol abuse within 12 month prior screen study entry 16 . Subject pregnant , able become pregnant practicing medicallyaccepted form birth control , and/or intend become pregnant study period</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>elbow</keyword>
</DOC>